Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organisation (CDMO), has announced a $90 million investment plan to expand two of its US facilities. The expansion is aimed at enhancing the company’s integrated offering, particularly in the area of antibody-drug conjugate (ADC) therapies. The two sites involved in the expansion are located in Riverview, Michigan, and Lexington, Kentucky.
The Riverview site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). The expansion at this site will add a commercial-scale suite for the development and manufacturing of payload-linkers, which are essential components of ADC therapies. The new suite is expected to be operational by the end of 2025.
The Lexington site is Piramal Pharma’s dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The expansion at this site will add commercial-scale sterile injectable manufacturing capabilities, including 24,000 additional square feet of manufacturing space, a new laboratory, and state-of-the-art machinery. The expansion is expected to be completed by late 2027.
The investment is driven by the growing demand for sterile injectables, which is projected to exceed $20 billion by 2028. Piramal Pharma’s Chairperson, Nandini Piramal, expressed confidence that the expansion will enable the company to meet the demands of this market and reinforce its position as a trusted global partner in biologic manufacturing. The expansion is expected to enhance the services provided to partners, ultimately reducing the burden of disease for more patients around the globe.
The expansion is a strategic move by Piramal Pharma to strengthen its presence in the biologic manufacturing market. The company’s ADCelerate platform, which provides integrated services for ADC therapies, is expected to benefit from the expansion. The new facilities will provide Piramal Pharma with the capacity to develop and manufacture complex biologic products, including ADCs, and will enable the company to support its partners in bringing new therapies to market. Overall, the investment is a significant step forward for Piramal Pharma and is expected to have a positive impact on the company’s growth and reputation in the industry.